ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation

Late-stage programs in GBS and GA are advancing, with strong clinical data and regulatory filings in progress. The GA study's unique focus on functional vision and mechanistic differentiation positions it for significant market impact, while the GBS program shows rapid, meaningful patient benefit a…